Amyris Inc (NASDAQ:AMRS) has partnered with Autodesk BioNano Research Group to launch open source tools for genetic design. The company announced that the new tools are developed to help rapidly drive the complex biological design of DNA construction. The tools were showcased at SynBioBeta SF 2016, in San Francisco, on October 4, 2016.

The company noted that current solutions are composed of a diverse collection of academic and industrial software. The problem with this is that these tools are difficult to acquire, learn and use effectively. As such, AMRS made use of its GSL to develop the Genetic Constructor. This tends to provide users with a graphical environment, as well as a genetic programming language. In its press release, Amyris noted that it expects the tools to help make significant progress in the biology sector, much like what early compilers did for the software industry.

However, that is not the only partnership that Amyris plans to benefit from. Earlier, the company announced that it had strengthened its partnership with a market leader in the nutraceuticals sector. The management believes that this would help AMRS expand its revenue, as compared to the original agreement, signed on April 27, 2016. As per the details of the new agreement, the two companies would acquire a new nutraceutical target, as well as secure a line of credit facility, worth $25 million, set to mature in a period of 5-years. The agreement also calls for a $5 million investment from one of the leading nutraceuticals manufacturer in the world.

Under the original agreement, Amyris had recently begun shipments of farnesene to the partner, which is aimed at helping it capture a larger share of the market. It should be noted here that this partner is developing a dedicated manufacturing facility, which will make use of the farnesene shipments and expand production volumes significantly. The company revealed that it expects its 1Q2017 revenues to include $40 million from the expanded partnership.

Amyris Inc (NASDAQ:AMRS) gained 10.12% in terms of its share value, during the October 10 trading session, to close at $0.644 per share.